# Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/SNDX/syndax-reports-first-quarter-2026-financial-results-and-provides-business-update
Ticker: SNDX
Company: Syndax Pharmaceuticals
Source: Syndax Pharmaceuticals
Published: 2026-04-30 20:01 EST
Original Source URL: https://ir.syndax.com
## Summary

– Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – – Revuforj ® (revumenib) net revenue of $48.9 million in 1Q26, highlighting leadership in menin inhibition and increasing uptake in R/R NPM1m AML – – Niktimvo™ (axatilimab-csfr) net revenue of $55.1 million in 1Q26,

## Article Body
– Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – – Revuforj ® (revumenib) net revenue of $48.9 million in 1Q26, highlighting leadership in menin inhibition and increasing uptake in R/R NPM1m AML – – Niktimvo™ (axatilimab-csfr) net revenue of $55.1 million in 1Q26,
## Recent Company News
- 2026-06-04 11:00 EST — [Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes](https://biopharmsignal.com/news/SNDX/syndax-announces-private-placement-of-250-0-million-of-convertible-senior-notes) — Source: Syndax Pharmaceuticals
- 2026-06-02 20:01 EST — [Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data](https://biopharmsignal.com/news/SNDX/syndax-highlights-revuforjr-revumenib-data-presented-at-asco-2026-including-an-oral-presentation-of-post-transplant-data) — Source: Syndax Pharmaceuticals
- 2026-06-01 11:00 EST — [Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026](https://biopharmsignal.com/news/SNDX/syndax-to-host-randd-day-highlighting-its-late-stage-programs-and-early-stage-assets-on-july-14-2026) — Source: Syndax Pharmaceuticals
- 2026-05-21 21:01 EST — [Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data](https://biopharmsignal.com/news/SNDX/syndax-announces-four-revuforjr-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data) — Source: Syndax Pharmaceuticals
- 2026-05-20 11:00 EST — [Syndax Announces Participation in Upcoming Investor Conferences](https://biopharmsignal.com/news/SNDX/syndax-announces-participation-in-upcoming-investor-conferences) — Source: Syndax Pharmaceuticals
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)